If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 171 - 180 of 265
A Phase 2, Randomized, Active-Controlled, Open-Label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants with Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previou
Objective
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer.
Protocol No
MERCK-MK6482-029
Categories
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
Objective
This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Protocol No
JNJ-75276617ALE1001
Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung D
Objective
Platform Clinical Study for Conquering Scleroderma
Protocol No
RHEU-SRF-CONQUEST
Categories
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain (VANISH)
Objective
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
Protocol No
SURG-ATRICURE-VANISH
Categories
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)- associated Vasculitis
Objective
Avacopan in Subjects With ANCA-associated Vasculitis
Protocol No
RHEU-AMGEN-GLAS
Categories
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients A
Objective
Testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia
Protocol No
SWOG-MM1YA-S01
Categories
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Objective
Comparing cytarabine + daunorubicin therapy versus cytarabine + daunorubicin + venetoclax versus venetoclax + azacitidine in younger patients with intermediate risk AML
Protocol No
CCTG-MM1YA-CTG01
Categories
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Objective
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML)
Protocol No
ECOG-MM1OA-EA02
Categories
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Objective
A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH
Protocol No
SWOG-MYELOMATCH
Categories
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
with cemiplimab with or without chemotherapy.
Protocol No
REGENERON-R7075-ONC-2009